Literature DB >> 10772527

Effect of food and pharmacokinetic variability on didanosine systemic exposure in HIV-infected children. Pediatric AIDS Clinical Trials Group Protocol 144 Study Team.

R C Stevens1, J H Rodman, F H Yong, V Carey, C A Knupp, L M Frenkel.   

Abstract

The effect of food on didanosine bioavailability and interpatient pharmacokinetic variability was examined in children infected with human immunodeficiency virus type 1 (HIV-1). Didanosine pharmacokinetics were determined during fasting and fed conditions in HIV-infected children enrolled in the Pediatric AIDS Clinical Trials Group Protocol 144 randomized to receive didanosine at 50 mg/m2 or 150 mg/m2 orally every 12 hr. Pharmacokinetic parameters from patients in the low (n = 39) and high (n = 38) dosing groups were not significantly different, but intersubject variability was substantial. The fraction absorbed was higher while fasting than with food (0.27+/-0.13 versus 0.19+/-0.09, p < 0.0001); the zero order absorption rate was faster (0.48+/-0.31 versus 0.76+/-0.72 hr, p = 0.003); and the plasma half-life was shorter (0.93+/-0.43 versus 1.39+/-0.65 hr, p < 0.0001). The lower fraction absorbed with food was offset by the absorption rate becoming rate limiting for elimination, resulting in similar areas under the concentration-time curves (normalized to 100 mg/m2) when fasted (853.9+/-465.8 microg/liter-hr) versus fed (796.3+/-367.5 microg/liter x hr). Oral clearances during fasting (152.5+/-81.7 liters/hr/m2) and fed states (163.6+/-99.3 liters/hr/m2) were similar, but these values in children are substantially higher than previously reported for adults. The systemic exposure (i.e., AUC) of didanosine was highly variable in children but similar in the presence and absence of food. Administration of didanosine with food in children may be permissible if total systemic exposure rather than maximum plasma concentration is sufficient for antiretroviral activity. The higher oral clearance and substantial pharmacokinetic variability suggest the need to reexamine current didanosine dose recommendations for HIV-infected children.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10772527     DOI: 10.1089/088922200309070

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  11 in total

Review 1.  Food-drug interactions.

Authors:  Lars E Schmidt; Kim Dalhoff
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 2.  Pharmacokinetic optimization of antiretroviral therapy in children and adolescents.

Authors:  Michael N Neely; Natella Y Rakhmanina
Journal:  Clin Pharmacokinet       Date:  2011-03       Impact factor: 6.447

Review 3.  Antiretroviral pharmacokinetics in the paediatric population: a review.

Authors:  Jennifer R King; David W Kimberlin; Grace M Aldrovandi; Edward P Acosta
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 4.  Pharmacokinetics of antiretroviral therapy in HIV-1-infected children.

Authors:  Pieter L A Fraaij; Jeroen J A van Kampen; David M Burger; Ronald de Groot
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 5.  Antiretroviral drugs in pediatric HIV-infected patients: pharmacokinetic and practical challenges.

Authors:  B Ryan Phelps; Natella Rakhmanina
Journal:  Paediatr Drugs       Date:  2011-06-01       Impact factor: 3.022

6.  Pharmacokinetics of stavudine and didanosine coadministered with nelfinavir in human immunodeficiency virus-exposed neonates.

Authors:  C Rongkavilit; P Thaithumyanon; T Chuenyam; B D Damle; S Limpongsanurak; C Boonrod; A Srigritsanapol; E A Hassink; R M Hoetelmans; D A Cooper; J M Lange; K Ruxrungtham; P Phanuphak
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

7.  Didanosine population pharmacokinetics in West African human immunodeficiency virus-infected children administered once-daily tablets in relation to efficacy after one year of treatment.

Authors:  Déborah Hirt; Christophe Bardin; Serge Diagbouga; Boubacar Nacro; Hervé Hien; Emmanuelle Zoure; François Rouet; Adama Ouiminga; Saik Urien; Vincent Foulongne; Philippe Van De Perre; Jean-Marc Tréluyer; Philippe Msellati
Journal:  Antimicrob Agents Chemother       Date:  2009-07-06       Impact factor: 5.191

8.  On the Design of Food Effect Studies in Adults for Extrapolating Oral Drug Absorption Data to Infants: an Exploratory Study Highlighting the Importance of Infant Food.

Authors:  Marina Statelova; Konstantinos Goumas; Nikoletta Fotaki; René Holm; Mira Symillides; Christos Reppas; Maria Vertzoni
Journal:  AAPS J       Date:  2019-12-02       Impact factor: 4.009

Review 9.  Nucleoside and nucleotide reverse transcriptase inhibitors in children.

Authors:  Carlo Giaquinto; Osvalda Rampon; Martina Penazzato; Federica Fregonese; Anita De Rossi; Ruggiero D'Elia
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

10.  Pharmacotherapy of pediatric and adolescent HIV infection.

Authors:  Susan J Schuval
Journal:  Ther Clin Risk Manag       Date:  2009-06-22       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.